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Abstract
Background: Insulin analogues comprising acidic amino acid substitutions at position B10 have previously been shown to
display increased mitogenic potencies compared to human insulin and the underlying molecular mechanisms have been
subject to much scrutiny and debate. However, B10 is still an attractive position for amino acid substitutions given its
important role in hexamer formation. The aim of this study was to investigate the relationships between the receptor
binding properties as well as the metabolic and mitogenic potencies of a series of insulin analogues with different amino
acid substitutions at position B10 and to identify a B10-substituted insulin analogue without an increased mitogenic to
metabolic potency ratio.
Methodology/Principal Findings: A panel of ten singly-substituted B10 insulin analogues with different amino acid side
chain characteristics were prepared and insulin receptor (both isoforms) and IGF-I receptor binding affinities using purified
receptors, insulin receptor dissociation rates using BHK cells over-expressing the human insulin receptor, metabolic
potencies by lipogenesis in isolated rat adipocytes, and mitogenic potencies using two different cell types predominantly
expressing either the insulin or the IGF-I receptor were systematically investigated. Only analogues B10D and B10E with
significantly increased insulin and IGF-I receptor affinities as well as decreased insulin receptor dissociation rates displayed
enhanced mitogenic potencies in both cell types employed. For the remaining analogues with less pronounced changes in
receptor affinities and insulin receptor dissociation rates, no apparent correlation between insulin receptor occupancy time
and mitogenicity was observed.
Conclusions/Significance: Several B10-substituted insulin analogues devoid of disproportionate increases in mitogenic
compared to metabolic potencies were identified. In the present study, receptor binding affinity rather than insulin receptor
off-rate appears to be the major determinant of both metabolic and mitogenic potency. Our results also suggest that the
increased mitogenic potency is attributable to both insulin and IGF-I receptor activation.
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Introduction
In order to improve insulin therapy for diabetic patients,
injectable insulin analogues with different pharmacokinetic profiles
have been developed to mimic the physiological plasma insulin
profiles of endogenously produced insulin. In the b-cell, HisB10
plays an important role in hexamer formation by the coordination
of zinc [1] and functions in processing and trafficking of insulin
through the secretory pathway [2]. An inverse relationship was
discovered between subcutaneous absorption and insulin self-
association, and this particular property of HisB10 guided the
design of the fast-acting X10 analogue (also known as AspB10) [3].
Insulin analogues displaying a reduced propensity towards self-
association were anticipated to act more rapidly than regular
human insulin and this was in fact demonstrated for insulin X10
[3,4].
Insulin and IGF-I are two closely related proteins that share
similarities in both primary and tertiary structure [5–7]. The
homology is paralleled by similarities in the structures of their
receptors, the insulin receptor (IR) and the IGF-I receptor (IGF-
IR) [8–10]. Insulin and IGF-I share a common overlapping
binding site on the two receptors, which comprises structural
differences in the regions governing ligand specificity [9,11].
Insulin and IGF-I therefore bind with high affinity to their cognate
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cognate receptor [7,12]. A commonly held view is that insulin
primarily induces metabolic effects, whereas IGF-I is thought to
regulate more mitogenic processes [13,14]. However, in the
proper cellular context, insulin can induce a mitogenic response
through the IR and inversely, IGF-I can exert insulin-like
metabolic effets through the IGF-IR [15,16].
Certain insulin analogues including insulin X10, have been
found to display disproportionately enhanced mitogenic compared
to metabolic potencies [17–19]. Compared to human insulin,
insulin X10 displays a 2-fold increase in metabolic potency, but a
significantly higher increase in the mitogenic activity compared to
human insulin of 3–20 fold depending on the cell type being
employed [17,18,20–22]. Unfortunately, insulin X10 also showed
an increased carcinogenic effect in female rats [23], and it has
therefore been tempting to speculate that this effect was associated
with the increased mitogenic potency; however, this has not been
proven and the precise molecular basis underlying the increased
tumorogenic potential is still unknown. Insulin X10 also has an
increased affinity for both the IR and the IGF-IR [17,19,21,24]
and a slower IR off-rate [18,19,24], but whether the increased
mitogenicity relates to the increased affinity for the IGF-IR, the
time of occupancy of the IR, or a combination of both IR and
IGF-IR-mediated effects has been much debated [25–27] and
remains to be fully elucidated.
Given the previous history with insulin X10, but taking into
account the distinctive properties attained by HisB10 replacement,
we wanted to examine the relationships between the receptor
binding properties as well as the metabolic and mitogenic
potencies of the analogues with different amino acid substitutions
at position B10 in order to explore the possibility of identifying a
B10-substituted insulin analogue without an increased mitogenic
to metabolic potency ratio seen for insulin X10. In this study,
several B10-substituted insulin analogues devoid of disproportion-
ate increases in mitogenic compared to metabolic potencies were
identified; of which B10V resembled human insulin the most.
Only analogues B10D and B10E with significantly increased IR
and IGF-IR affinities as well as decreased IR dissociation rates
displayed enhanced mitogenic potencies in both cell types
employed for mitogenicity determination.
Materials and Methods
Materials
Human insulin, [
125I]-TyrA14-labelled insulin, human IGF-I,
[
125I]-Tyr31-labelled IGF-I, and immobilized Achromobacter lyticus
(ALP) protease were from Novo Nordisk A/S. Receptor binding
assays were performed using solubilized human IR and human
IGF-IR semipurified by wheat germ agglutinin chromatography
(according to the method from [28]) from baby hamster kidney
(BHK) cells, which were stably transfected with the pZem vector
containing either the human IR isoform A (IR-A), IR isoform B
(IR-B) or IGF-IR insert (as recently described by [29]). Rats
(Wistar, male, 150–200g) were acquired from an authorized
breeding company (Taconic Europe A/S, Lille Skensved, Den-
mark) and housed according to standard procedures until sacrifice.
The experiments with the primary rat adipocytes were performed
according to the Animal Experiments Inspectorate (The Danish
National Authority, proclamation no. 1273, December 8
th 2008
based on the animals rights law no. 1343 of December 12
th 2007),
where tissue sampling from sacrificed animals does not require a
permit. The IR-specific antibody 83-7 [30], IGF-IR specific
antibody 24–31 [31] were licensed from Dr. K. Siddle (University
of Cambridge, Cambridge, UK). Other chemicals used were of
analytical grade or higher from Sigma-Aldrich.
Cells
BHK cells overexpressing the A-isoform of the human insulin
receptor (BHK-hIR) were prepared essentially as described in [32]
(parent cell line BHK tk-ts13, cat. no. CRL-1632, ATCC). The L6
rat muscle myoblast cell line stably transfected with the human IR-
A (L6-hIR) were the same as recently described [33] (parent cell
line L6, cat. no. CRL-1458, ATCC). CloneticsH Human mam-
mary epithelial cells (HMECs) were obtained from Lonza,
Walkersville Inc., USA (cat. no. CC2251).
Analogue expression, purification and labelling
Vector construction, precursor expression, conversion by ALP,
quantification, and purification of the insulin analogues were
performed as previously described (in [34] and references therein).
In brief, insulin precursor DNA constructs were transformed into
Saccharomyces cerevisiae (strain MT663) and expressed as proinsulin-
like fusion proteins with a removable N-terminal spacer peptide
and a mini C-peptide. The secreted analogue precursors were
captured from cell-free acidified culture supernatant on a cation
exchange column. The eluted precursors were enzymatically
converted into mature two-chain desB30 insulin analogues (lacking
the amino acid at position B30) by ALP treatment and further
purified by preparative reverse-phase high-performance liquid
chromatography, from which the main protein peak was collected
and lyophilized. Full conversion of the resulting desB30 analogues
were verified by matrix-assisted laser desorption ionization time-
of-flight mass spectrometry. Analogue concentrations and purity
were determined by reverse-phase high-performance liquid
chromatography. [
125I]-TyrA14-labelled analogues were prepared
using the lactoperoxidase method as previously published [35].
Binding assays
IR competition binding assays were performed on both
isoforms of the receptor in a scintillation proximity assay as
recently published [34]. IGF-IR competition binding assays were
conducted essentially as the IR binding assays in 96-well plates
(OptiPlate-96, PerkinElmer Life Sciences) on an Eppendorf
epMotion 5075 robot. Assays were initiated by making dilution
series (nine dilutions, 5-fold each) in binding buffer of a purified
human insulin standard (starting from 7.5 mM) and a purified
insulin analogue (starting from 7.5 mM) or IGF-I (starting from
0.1 mM) (n=4 on each plate for the human insulin standard,
insulin analogue or IGF-I) followed by addition of [
125I]-labelled
IGF-I, anti-IGF-IR mouse antibody (24–31), solubilized human
IGF-IR, and scintillation proximity assay beads (SPA PVT
Antibody-Binding Beads, Anti-Mouse Reagent, GE Healthcare)
resuspended in binding buffer. The solubilized receptors were
used at a suitable concentration, adjusted to give ,20% bound
tracer when no competing ligand was added to avoid ligand
depletion. The buffer consisted of 100 mM HEPES (pH 7.8),
100 mM NaCl, 10 mM MgSO4, and 0.025% (v/v) Tween-20.
Plates were incubated with gentle shaking for 24 h at 22uC,
centrifuged, and counted in a TopCount NXT (PerkinElmer Life
Sciences). IC50 values were determined using the four parameter
logistic model [36] assuming constant slope, basal and maximal
response. The IR affinities (picomolar affinity range) and the
IGF-IR affinities (nanomolar affinity range) of the insulin
analogues were calculated relative to that of the human insulin
standard [IC50(human insulin)/IC50(analogue)6100%] measured with-
in the same plate.
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Metabolic potencies were determined by lipogenesis (rFFC
assay) using isolated primary rat adipocytes essentially as described
in [37,38]. Briefly, the epididymal fat pads were removed from
killed Wistar rats and placed in degradation buffer (Krebs buffer,
1% HSA, 4 mg/mL collagenase (Worthington), and 2 mg/mL
glucose) under vigorous shaking for 1 h at 37uC. The cell
suspension was filtered, washed twice, and resuspended in
incubation buffer (Krebs buffer, 1% HSA). Aliqouts of 100 mL
were incubated for 2 h with gentle shaking at 37uC in 96-well
PicoPlates (PerkinElmer Life Sciences) with 10 mL of glucose
solution containing 12.5 mL/mL D-[3-
3H]-glucose (GE Health-
care) and 0.08 mg/mL glucose together with 10 mL of increasing
concentrations of human insulin or insulin analogue. The
incubation was stopped by the addition of 150 mL MicroScint-E
(Packard) and plates were counted in a TopCount NXT. EC50
values (picomolar range) were determined using the four
parameter logistic model [36] and the metabolic potencies of the
insulin analogues were calculated relative to that of the human
insulin standard [EC50(human insulin)/EC50(analogue)6100%] mea-
sured within the same plate.
Mitogenic potency determination
HMECs were maintained according to the manufactures
recommendations in mammary epithelial growth media (MEGMH)
containing SingleQuotsH of supplements and growth factors (bovine
pituitary extract, hydrocortisone, epidermal growth factor, insulin
and gentamicin/amphotericin-B) (all from Cambrex). For experi-
ments, cells were seeded at a density of 4610
3 cells/well in 96-well
plates and incubated for 24 h in assay medium (MEGMH except
insulin) after which increasing concentrations of ligand were added.
Plates were incubated for 72 h at which 0.125 mCi/well [
3H]-
thymidine (Amersham Biosciences) was added at t=70 h. Cells
were harvested using a cell harvester and scintillation liquid added
to the dried filter plates after which radioactivity was counted in a
TopCount NXT (all from PerkinElmer Life Sciences). Potencies
were calculated relative to that of the human insulin standard
[EC50(human insulin)/EC50(analogue)6100%] measured within the same
plate. The dose-response curves were fitted by non-linear regression
using GraphPad Prism 4 (GraphPad Software, Inc).
L6-hIR cells were cultured at 37uC in a 5% CO2 humidified
atmosphere in Nunc culture flasks with growth medium con-
sisting of Dulbecco’s Modified Eagle Medium (DMEM) supple-
mented with 10% (v/v) FBS, 1% (v/v) Pen/Strep/Glu and
1 mg/ml G418 (all from Gibco). Cells were subcultured 3 times
per week with a split ratio of 1:10 for two days and 1:20 for three
days. DNA synthesis was quantified as [
3H]-thymidine incorpo-
ration into genomic DNA according to an optimized method by
C. Bonnesen and M. B. Oleksiewicz (personal communication).
Briefly, the rat L6 myoblasts overexpressing the A-isoform of the
human insulin receptor were synchronized by topoinhibition and
serum starvation and stimulated for 18–19 hours in medium
containing 0.1% serum supplemented with increasing concentra-
tions of ligand. The cells were pulse-labelled with 0.125 mCi/well
of [
3H]-thymidine for 2 h and transferred to filter plates using a
cell harvester. Subsequently, 30 mL/well of Microscient O
scintillation liquid was added to the dried filter plates and
radioactivity measured in a TopCount NXT (all from PerkinEl-
mer Life Sciences). The mitogenic potencies were calculated
relative to that of the human insulin standard [EC50(human insulin)/
EC50(analogue)6100%] measured within the same plate by non-
linear regression using GraphPad Prism 5 (GraphPad Software,
Inc).
Determination of insulin receptor dissociation rate
constants
BHK-hIR cells were cultured at 37uC in a 5% CO2 humidified
atmosphere in Nuncleon culture flasks with growth medium
consisting of DMEM supplemented with 10% (v/v) FBS, 100 mg/
ml streptomycin, 100 U/ml penicillin (all from Cambrex),
and 1 mmol/L methotrexate (Lonza). Cells were subcultured at a
1:25 split ratio every 3–4 days for routine maintenance. For
experiments, cells were seeded on 24-well Nunclon plates coated
with Poly-L-lysine at a density of 8610
3 cells/well (adjusted to give
5–10% bound tracer in the absence of unlabelled ligand) in growth
medium. Cells were used at ,80% confluence and were incubated
with [
125I]-labelled human insulin or insulin analogue (50 pM final
concentration) for 2.5 h at 4uC. Cells were washed quickly with
ice-cold assay buffer consisting of DMEM with 0.1% (v/v) c-
globulin and Complete
TM protease inhibibitor mixture (Roche
Diagnostics). The dissociation of radioactively labelled ligand was
measured at different time points after the addition of assay buffer
containing 1 mM unlabelled human insulin at 4uC. The receptor-
bound tracer was counted on a Cobra II c-counter (PerkinElmer
Life Sciences) and the dissociation rate constants were calculated
using GraphPad Prism 4 (GraphPad Software, Inc).
Results and Discussion
A series of ten different insulin analogues each comprising a
single amino acid substitution at position B10 were systematically
evaluated with respect to IR-A, IR-B, and IGF-IR binding, IR off-
rates as well as metabolic and mitogenic potencies compared to
human insulin. The B10H analogue (desB30 human insulin) was
included in all the assays, thus serving as an internal control. The
analogues tested were B10A, B10R, B10D, B10Q, B10E, B10H,
B10I, B10F, B10W, and B10V, which represent a diverse panel of
insulin analogues with different amino acid side chain character-
istics at position B10.
Insulin receptor binding
The relative insulin receptor binding affinities of the analogues
were determined using human insulin receptors (full-length)
purified from BHK cells (see Table 1 and Figure 1). For each
analogue, receptor binding affinities were determined on both the
A and B isoform of the IR. All the analogues displayed a balanced
IR-A/IR-B affinity ratio (R
2=0.99, p,0.0001 between the
relative IR-A and IR-B binding affinities). As previously
determined [34,39,40], the negatively charged Asp and Glu
substitutions (analogues B10D and B10E) caused 3-4-fold increases
in IR affinity, while analogues B10Q, B10I, and B10F exhibited
only moderately enhanced IR binding affinities. The most
pronounced decrease in receptor binding (5-fold) was observed
for the B10R analogue, whereas analogues B10A and B10W
displayed 2-fold reductions in IR binding affinity. Analogue B10V
had a relative IR affinity close to that of human insulin.
IGF-I receptor binding
The relative IGF-I receptor binding affinities of the analogues
were determined using human IGF-I receptors (full-length)
purified from BHK cells. As can be seen from Table 1 and
Figure 1, the IGF-IR was more affected by the amino acid
substitutions than the IR and the relative affinities ranged from
28% for B10R to 1151% for B10E. Compared to IR binding,
analogue B10E had a 3-fold higher relative IGF-IR binding
affinity (L. Scha ¨ffer [41] determined the difference to be 2-fold),
which in agreement with the fact that the amino acid residue
corresponding to HisB10 in insulin is a Glu residue in the
B10-Substituted Insulin Analogues
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very important in IGF-IR binding [42].
Interestingly, the internal desB30 human insulin control (B10H)
displayed a slight increase in relative binding affinity compared to
human insulin, indicating that the basic C-terminal LysB29
residue has an impact on IGF-IR binding as opposed to IR
binding, which is unaffected by the removal of ThrB30. This
phenomenon was also observed in a previous study [20], in which
B10D, desB30 was found to have a higher affinity for the IGF-IR
than the corresponding full-length B10D analogue (insulin X10).
In this study, the B10D analogue displayed a 5-fold increase in
IGF-IR binding compared to human insulin, which is in good
agreement with earlier results [20]. Analogues with decreases in IR
binding affinities compared to human insulin also had decreased
IGF-IR binding affinities and ranked in the same order on both
receptor types. Analogue B10F displayed a small increase in IGF-
IR compared to IR binding as with analogue B10H, whereas the
opposite was observed for the B10Q analogue. The B10V
analogue displayed a balanced IR to IGF-IR binding affinity
ratio and had a relative affinity close to that of human insulin.
Metabolic potency
The metabolic potencies of the analogues were determined by
measuring the dose-dependent stimulation of lipogenesis over a
2 h period in isolated rat adipocytes (see Table 1). The dose-
response curves for the analogues and human insulin exhibited no
significant differences in minimal and maximal responses (,12-
fold stimulation) or in the slopes. The metabolic potencies ranged
from 27% for B10W to 226% for B10E relative to that of human
insulin. As observed in both the IR and IGF-IR binding
experiments, analogues B10D and B10E were the most potent
analogues in this assay and the metabolic potencies determined in
this study are in good agreement with previous findings [18].
Compared to the relative IR binding potencies, analogues B10A
and B10R were more metabolically potent; whereas the metabolic
potencies of analogues B10I, B10F, and B10W were 2–2.5-fold
lower than their relative IR binding affinities. Analogues B10Q
and B10V only displayed slight decreases in relative metabolic
potency compared to IR binding. It has previously been shown for
several different insulin analogues that their metabolic potencies
correlated well with their equilibrium IR binding affinities [17,19];
Figure 1. Relative receptor binding affinities. Receptor binding affinities for the solubilised IR-A (light teal), IR-B (dark teal) and IGF-IR (gray)
relative to human insulin. The gray dotted line represents 100% binding affinity compared to that of human insulin. Data are means 6 SD (n=3).
doi:10.1371/journal.pone.0029198.g001
Table 1. Relative receptor affinities, metabolic and mitogenic potencies, and IR off-rates [% of human insulin].
Receptor binding Lipogenesis Mitogenic potency
Analogue IR-A IR-B IGF-IR rFFC HMEC L6-hIR IR off-rate
B10A 51 6 55 86 53 8 6 37 46 12 25 6 74 3 6 88 6 6 2
B10R 21 6 22 46 22 8 6 24 66 63 76 16 18 6 21 4 9 6 7
B10D 297 6 21 285 6 31 548 6 59 215 6 22 568 6 165 221 6 43 20 6 0.3
B10Q 137 6 5 139 6 10 109 6 71 0 3 6 20 180 6 54 101 6 18 83 6 2
B10E 382 6 30 399 6 22 1151 6 77 226 6 23 888 6 257 257 6 127 14 6 2
B10H 105 6 1 107 6 3 122 6 89 86 10 86 6 25 92 6 21 101 6 6
B10I 118 6 6 113 6 6 113 6 26 16 11 69 6 19 38 6 56 8 6 3
B10F 135 6 6 134 6 4 167 6 15 52 6 39 06 14 48 6 35 4 6 1
B10W 60 6 26 56 45 3 6 22 76 10 39 6 12 38 6 14 6 6 1
B10V 90 6 10 85 6 18 4 6 66 76 13 65 6 30 97 6 24 93 6 6
All assays were performed in at least three independent experiments. Data are means 6 SD and presented relative to human insulin. For human insulin, IR assay IC50
values were in the picomolar affinity range, IGF-IR assay IC50 values were in the nanomolar affinity range, rFFC assay EC50 values were in the picomolar range, and
mitogenic assay EC50 values were in the nanomolar range (HMECs) and low nanomolar range (L6-hIR). The dissociation rate constant for human insulin was
(3.760.3610
22 min
21).
doi:10.1371/journal.pone.0029198.t001
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(including B10D and B10E) displayed slightly decreased relative
metabolic potencies compared to relative IR binding potencies
and a less pronounced degree of correlation (R
2=0.87, p,0.0001)
between IR binding and metabolic potency of the B10 analogues
was observed. As with IR binding, the internal desB30 insulin
control displayed the same relative potency as human insulin.
Mitogenic potency
To assess the mitogenic potencies of the analogues, two different
cell types predominantly expressing either the IR or the IGF-IR,
were employed in order to detect the mitogenic effects of the
analogues mediated mainly through either of the two receptor
types. Cell growth was determined by [
3H]-thymidine incorpora-
tion into DNA in the rat L6 myoblast cell line overexpressing the
human IR-A (L6-hIR) as well as in primary, non-transformed
human mammary epithelial cells (HMECs), which express
approximately 20-fold more IGF-I receptors than insulin receptors
[20]. In both assays, no significant differences in minimal and
maximal responses or in the slopes of the dose-response curves
were observed between human insulin and the insulin analogues
(see Figure 2). In the HMECs, maximal stimulation caused a 3–6-
fold increase in growth response over basal (EC50 values were in
the nM range), while ,20-fold responses were observed in the L6-
hIR cells (EC50 values were in the low nM range). The absolute
mitogenic potency of human insulin was therefore lower in the
HMECs compared to L6-hIR cells as expected if the effect was
mediated by the IGF-IR in the HMECs, but through the IR in the
L6-hIR cells. The relative mitogenic potencies of the analogues
compared to human insulin are presented in Table 1.
The broader range of receptor binding affinities determined on
the IGF-IR compared to the IR was paralleled in the mitogenic
potencies of the analogues, where potencies ranged from 18% to
257% in the L6-hIR cells and from 25% to 888% in the HMECs. In
general, the relative mitogenic potencies determined in HMECs
correlated (R
2=0.96, p,0.0001) with the relative IGF-IR binding
affinities of the analogues, whilea correlation (R
2=0.90, p,0.0001),
though less pronounced, was observed between the relative IR
binding affinities and the relative mitogenic potencies determined in
the L6-hIR cells. This is in good agreement with previous reports
[17,20,43] in which analogues with increased IGF-IR binding
affinities were found to induce enhanced mitogenic responses in cells
expressing a high proportion of IGF-I receptors compared to insulin
receptors.
Only analogues B10D and B10E were more potent than human
insulin in stimulating cell growth in both cell systems. Compared
to human insulin, B10D and B10E displayed 2- and 3-fold
increases in relative mitogenic potencies in the L6-hIR cells, while
6-fold and 9-fold increases were observed in the HMECs,
respectively. Analogue B10Q, which exhibits the highest degree
of structural resemblance to B10E, displayed almost a 2-fold
increase in mitogenic potency in the HMECs, while the remainder
of the analogues were less mitogenic than human insulin in both of
the cell types employed. The correlation between IGF-IR binding
and mitogenicity measured in the HMECs as well as the
correlation between IR binding and mitogenic potency measured
in L6-hIR cells were therefore also less obvious, when looking at
the analogues with relatively small changes in IGF-IR binding
affinity compared to human insulin. Analogue B10H displayed
relative mitogenic potencies comparable to that of human insulin
in both cell types employed even though its IGF-IR binding
affinity was slightly higher than that of human insulin.
In general, the mitogenic potencies determined in L6-hIR cells
correlated well (R
2=0.95, p,0.0001) with the metabolic potencies
of the analogues. This was also valid for analogues B10D and
B10E, which were equally potent in both the rFFC and the L6-
hIR assay. However, when comparing the metabolic potencies
with the mitogenic potencies of the analogues determined in
HMECs, no clear correlation was identified. Analogues B10D and
B10E with highly increased receptor affinities, showed 3–4-fold
increases in the mitogenic (HMEC) to metabolic potency ratio,
respectively. Taking the distribution of insulin and IGF-I receptors
as well as the correlations between mitogenicity and receptor
binding into account, it seems that the mitogenic response
measured in the HMECs predominantly was mediated through
the IGF-I receptor, whereas the mitogenic potency of the
analogues in the L6-hIR cells mainly was mediated via the insulin
receptor.
Insulin receptor dissociation rates
The dissociation rate constants from the insulin receptor were
determined using BHK cells overexpressing the human IR-A.
Dissociation of [
125I]-labelled human insulin or insulin analogue
was determined as a function of time in the presence of an excess
of unlabelled insulin. Representative dissociation time courses are
presented in Figure 3 and the results and the dissociation rate
constants relative to human insulin (3.760.3610
22 min
21) are
listed in Table 1. Dissociation was measured over a period of
Figure 2. Representative dose-response profiles for mitogenic potency determination. Human insulin (N) or insulin analogue (B10D (¤),
B10E (&), or B10A (.)) stimulated incorporation of [
3H]-thymidine into DNA is shown in (A) L6-hIR cells and (B) HMECs. Data points are means 6 SEM
(n=3).
doi:10.1371/journal.pone.0029198.g002
B10-Substituted Insulin Analogues
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fold slower from the receptor, respectively, compared to human
insulin and dissociation was therefore measured over a 5 h period
for these two analogues in order to get a better curve fit and
thereby a more precise determination of the dissociation rate
constant.
Analogues B10Q, B10I, and B10F, which all displayed slight
increases in IR binding affinity, also displayed a slower dissociation
from the IR than human insulin. Analogue B10W clearly had a
more flat dissociation curve than human insulin and exhibited a 2-
fold decrease in IR dissociation rate even though it displayed a
relative IR binding affinity lower than human insulin. However,
the relative IR affinity was determined by equilibrium binding and
the decrease in off-rate may therefore be paralleled by a decrease
in on-rate, but association rates were not determined in this study.
Analogues B10A and B10R displayed 2-fold and 5-fold reductions
in relative IR binding affinity, respectively, but whereas B10R
displayed a 1.5-fold increase in IR off-rate, analogue B10A
exhibited a minor decrease in off-rate. This may again be
counterbalanced by a decrease in the IR on-rate in order to
achieve a 2-fold reduction in IR binding affinity, but it may also be
attributable to an underestimation of the accelerated dissociation
[44], which is most evident in the initial phase of the dissociation
curve.
It has been observed in previous studies that insulin analogues
with increased mitogenic potencies dissociated very slowly from
the IR. The sustained activation of the IR was found to correlate
with increased mitogenicity, suggesting that the enhanced
mitogenic response was attributable to an increased duration of
the insulin signal at the receptor level [14,18,19]. In the present
study, analogues B10D and B10E displayed very low IR
dissociation rates of 20% and 14%, respectively, relative to human
insulin, which was paralleled by similar increases in the mitogenic
potencies when measured in the HMECs. The mitogenic (HMEC)
to metabolic potency ratio of these slowly dissociating analogues
was increased by 3 fold for B10D and 4 fold for B10E. In the L6-
hIR cells on the other hand, the 5- and 7-fold decreases in IR off-
rate exceeded that of the approximate 2-fold increases in
mitogenic potency. While analogues B10D and B10E displayed
the lowest IR-off rates and highest mitogenic potencies, the
correlation between receptor dissociation rate and mitogenicity
was less clear for the remaining B10 analogues. The aromatically
substituted B10F and B10W analogues both exhibited 2-fold
decreases in IR off-rate, but were less mitogenic than human
insulin in the two cell types employed. The dissociation rates of
analogues B10H and B10V were similar to that of human insulin.
Concluding remarks
It would be of great interest to fully elucidate the molecular
mechanisms underlying the enhanced mitogenicity observed for
certain insulin analogues. However, the analysis of the metabolic
and mitogenic effects elicited by the IR and IGF-IR both in vitro
and in vivo is complicated. Factors complexifying clarification
include co-expression of the receptors on the cell surface of most
cells and the formation of hybrids [45–47], the large homology
and structural resemblance of insulin and IGF-I as well as their
receptors leading to non-cognate receptor binding [7,8,10], and
the overlapping signalling pathways involving phosphorylation of
the same intracellular receptor substrates and downstream
signalling molecules [13,48]. In addition, insulin analogues may
also exhibit differences in their susceptibility to degradation and
cellular processing [49,50] that may influence their metabolic as
well as mitogenic potencies thus complicating comparison of the
biological properties of different insulin analogues in order to
deduce the molecular characteristics affecting the metabolic/
mitogenic potency ratio.
Recent reports have also suggested that the IR isoform
expression pattern [47,51], the IR/IGF-IR ratio expressed on
the cell surface [25] as well as internalization and signalling from
different cellular compartments play a role in determining the
mitogenicity of insulin analogues [52–54]. The metabolic and
mitogenic properties of insulin analogues may therefore result
from a complex combination of the expression levels of signalling
molecules (e.g. IRSs and Shcs) as well as the different events taking
place upon and after receptor binding and are therefore not fixed
inherent characteristics, but depend on cell type and the specific
biological end-point being studied.
Previous studies investigating the mitogenicity of insulin
analogues with amino acid substitutions at position B10 have
only included analogues with acidic Asp or Glu substitutions, but
Figure 3. Representative dissociation curves of [
125I]-labelled insulin or analogue from BHK-hIR cells. Dissociation was measured at
different time points and the residual binding expressed as a percentage of initial binding. Dissociation of (A) B10D (¤) and B10E (&); (B) B10W (m),
human insulin (N), and B10R (.). Data points are means 6 SEM (n=3).
doi:10.1371/journal.pone.0029198.g003
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comprising different side chain characteristics were systematically
examined. Even though analogues B10D and B10E displayed
increased mitogenic potencies and dissociated very slowly from the
IR, no apparent correlation between insulin receptor occupancy
time and mitogenicity was observed for the remaining B10-
substituted insulin analogues with less pronounced changes in
receptor affinities and IR dissociation rate constants. Instead, the
presented data suggest that receptor binding affinity rather than
insulin receptor off-rate seem to be the main predictor of both
metabolic and mitogenic potency.
Together, our results suggest that the enhanced mitogenicity is
attributable to both IR and IGF-IR activation, which is in good
agreement with the fact that the two receptors share a common
binding site. However, we also show that minor increases in
receptor binding alone do not entail increased mitogenicity. Only
the acidic Asp and Glu substitutions, which give rise to highly
increased IR and IGF-IR binding affinities and at the same time,
resemble the acidic substitution found at the corresponding
position in IGF-I the most, entail significantly increased mitogenic
potencies compared to human insulin in both cell types employed.
This would suggest that future insulin analogues featuring ‘IGF-I-
like’ substitutions causing significant increases in both IR and IGF-
IR affinity and an enhanced mitogenic/metabolic potency ratio
should be avoided.
In summary, several B10-substituted insulin analogues devoid of
disproportionate increases in mitogenic compared to metabolic
potencies were identified; of which analogue B10V taken as a
whole resembled human insulin the most. Depending on the
desired properties of future insulin analogues comprising a B10
substitution, the different physico-chemical properties of the
amino acid side chain properties will have to be determined and
taken into account.
Acknowledgments
We thank Annette F. Bjerre, Lene S. Walander, Peter Riis, Linda K.
Nielsen, Lenette S. Jørgensen, Mette Frost, and Marianne Schiødt for
excellent technical assistance. We also thank Pernille U. Bolvig and Gitte
Mai-Nelander for contributing with L6-hIR data, Jesper B. Kristensen for
radioactive labelling of the analogues, and Lars H. Christensen for the
fermentation of analogue strains.
Author Contributions
Conceived and designed the experiments: TG TK ARS EN. Performed the
experiments: TG LK ACH. Analyzed the data: TG LK ACH ARS CES
TK. Wrote the paper: TG. Revised the manuscript for important
intellectual content: BFH.
References
1. Emdin SO, Dodson GG, Cutfield JM, Cutfield SM (1980) Role of zinc in insulin
biosynthesis: Some possible zinc-insulin interactions in the pancreatic b-cell.
Diabetologia 19: 174–182.
2. Carroll RJ, Hammer RE, Chan SJ, Swift HH, Rubenstein AH, et al. (1988) A
mutant human proinsulin is secreted from islets of Langerhans in increased
amounts via an unregulated pathway. Proc Natl Acad Sci USA 85: 8943–
8947.
3. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, et al. (1988) Monomeric
insulins obtained by protein engineering and their medical implications. Nature
333: 679–682.
4. Heinemann L, Starke AAR, Heding L, Jensen I, Berger M (1990) Action profiles
of fast onset insulin analogs. Diabetologia 33: 384–386.
5. Baker EN, Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, et al. (1988) The
structure of 2Zn pig insulin crystals at 1.5 A ˚ resolution. Philos Trans R Soc
London B 319: 369–456.
6. Humbel RE (1990) Insulin-like growth factor-I and factor-II. Eur J Biochem
190: 445–462.
7. De Meyts P (2004) Insulin and its receptor: Structure, function and evolution.
BioEssays 26: 1351–1362.
8. Adams TE, Epa VC, Garrett TPJ, Ward CW (2000) Structure and function of
the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 57: 1050–1093.
9. Lou MZ, Garrett TPJ, McKrn NM, Hoyne PA, Epa VC, et al. (2006) The first
three domains of the insulin receptor differ structurally from the insulin-like
growth factor 1 receptor in the regions governing ligand specificity. Proc Natl
Acad Sci USA 103: 12429–12434.
10. Mckern NM, Lawrence MC, Streltsov VA, Lou MZ, Adams TE, et al. (2006)
Structure of the insulin receptor ectodomain reveals a folded-over conformation.
Nature 443: 218–221.
11. Kjeldsen T, Andersen AS, Wiberg FC, Rasmussen JS, Scha ¨ffer L, et al. (1991)
The ligand specificities of the insulin receptor and the insulin-like growth factor-I
receptor reside in different regions of a common binding site. Proc Natl Acad Sci
USA 88: 4404–4408.
12. Frasca F, Pandini C, Scalia P, Sciacca L, Mineo R, et al. (1999) Insulin receptor
isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor
in fetal and cancer cells. Mol Cell Biol 19: 3278–3288.
13. Siddle K, Ursø B, Niesler CA, Cope DL, Molina L, et al. (2001) Specificity in
ligand binding and intracellular signalling by insulin and insulin-like growth
factor receptors. Biochem Soc T 29: 513–525.
14. De Meyts P (1994) The structural basis of insulin and insulin-like growth factor-I
receptor binding and negative cooperativity, and its relevance to mitogenic
versus metabolic signaling. Diabetologia 37: S135–S148.
15. Ish-Shalom D, Christoffersen CT, Vorwerk P, Sacerdoti-Sierra N, Shymko RM,
et al. (1997) Mitogenic properties of insulin and insulin analogues mediated by
the insulin receptor. Diabetologia 40: S25–S31.
16. Baudry A, Lamothe B, Bucchini D, Jami J, Montarras D, et al. (2001) IGF-1
receptor as an alternative receptor for metabolic signaling in insulin receptor-
deficient muscle cells. FEBS Lett 488: 174–178.
17. Kurtzhals P, Scha ¨ffer L, Sørensen A, Kristensen C, Jonassen I, et al. (2000)
Correlations of receptor binding and metabolic and mitogenic potencies of
insulin analogs designed for clinical use. Diabetes 49: 999–1005.
18. Hansen BF, Danielsen GM, Drejer K, Sørensen AR, Wiberg FC, et al. (1996)
Sustained signalling from the insulin receptor after stimulation with insulin
analogues exhibiting increased mitogenic potency. Biochem J 315: 271–279.
19. Drejer K (1992) The bioactivity of insulin analogs from in vitro receptor binding
to in vivo glucose uptake. Diabetes Metab Rev 8: 259–285.
20. Slieker LJ, Brooke GS, DiMarchi RD, Flora DB, Green LK, et al. (1997)
Modifications in the B10 and B26-30 regions of the B chain of human insulin
alter affinity for the human IGF-I receptor more than for the insulin receptor.
Diabetologia 40: S54–S61.
21. Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R (1997) ASPB10 insulin
induction of increased mitogenic responses and phenotypic changes in human
breast epithelial cells: Evidence for enhanced interactions with the insulin-like
growth factor-I receptor. Mol Carcinogen 18: 19–25.
22. Sommerfeld MR, Muller G, Tschank G, Seipke G, Habermann P, et al. (2010)
In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
PLoS One 5: e9540. DOI:10.1371.
23. Jørgensen LN, Dideriksen LH, Drejer K (1992) Carcinogenic effect of the
human insulin analog B10Asp in female rats. Diabetologia 35: A3.
24. Hansen BF, Stidsen CE, Glendorf T, Lundby A, Hegelund AC, et al. (2010)
Safety analysis of basal insulins: Mitogenic potency and receptor binding.
Diabetologia 53(Suppl 1): S22.
25. Hansen BF (2008) Insulin analogues with increased mitogenic potency - Are they
safe? Horm Metab Res 40: 431–433.
26. Jensen M, De Meyts P (2009) Molecular mechanisms of differential intracellular
signaling from the insulin receptor. Vitam Horm 80: 51–75.
27. Hansen BF, Kurtzhals P, Jensen AB, Dejgaard A, Russell-Jones D (2011) Insulin
X10 revisited: a super-mitogenic insulin analogue. Diabetologia;DOI:10.1007/
s00125-011-2203-8.
28. Fujita-Yamaguchi Y, Choi S, Sakamoto Y, Itakura K (1983) Purification of
insulin receptor with full binding activity. J Biol Chem 258: 5045–5049.
29. Slaaby R, Scha ¨ffer L, Lautrup-Larsen I, Andersen AS, Shaw AC, et al. (2006)
Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I
receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR
splice variant. J Biol Chem 281: 25869–25874.
30. Soos MA, Siddle K, Baron MD, Heward JM, Luzio JP, et al. (1986) Monoclonal
antibodies reacting with multiple epitopes on the human insulin receptor.
Biochem J 235: 199–208.
31. Soos MA, Field CE, Lammers R, Ullrich A, Zhang B, et al. (1992) A panel of
monoclonal antibodies for the type-I insulin-like growth factor receptor. Epitope
mapping, effects on ligand binding, and biological activity. J Biol Chem 267:
12955–12963.
32. Andersen AS, Kjeldsen T, Wiberg FC, Christensen PM, Rasmussen JS, et al.
(1990) Changing the insulin receptor to possess insulin-like growth factor-I
ligand specificity. Biochemistry 29: 7363–7366.
B10-Substituted Insulin Analogues
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e2919833. Jensen M, Hansen B, De Meyts P, Scha ¨ffer L, Ursø B (2007) Activation of the
insulin receptor by insulin and a synthetic peptide leads to divergent metabolic
and mitogenic signaling and responses. J Biol Chem 282: 35179–35186.
34. Glendorf T, Sørensen AR, Nishimura E, Pettersson I, Kjeldsen T (2008)
Importance of the solvent-exposed residues of the insulin B chain a-helix for
receptor binding. Biochemistry 47: 4743–4751.
35. Drejer K, Kruse V, Larsen UD, Hougaard P, Bjørn S, et al. (1991) Receptor
binding and tyrosine kinase activation by insulin analogs with extreme affinities
studied in human hepatoma HepG2 cells. Diabetes 40: 1488–1495.
36. Vølund A (1978) Application of four-parameter logistic model to bioassay:
Comparison with slope ratio and parallel line models. Biometrics 34: 357–365.
37. Rodbell M (1964) Metabolism of isolated fat cells. I. Effects of hormones on
glucose metabolism and lipolysis. J Biol Chem 239: 375–380.
38. Moody AJ, Stan MA, Stan M, Gliemann J (1974) Simple free fat cell bioassay for
insulin. Horm Metab Res 6: 12–16.
39. Kaarsholm NC, Norris K, Jørgensen RJ, Mikkelsen J, Ludvigsen S, et al. (1993)
Engineering stability of the insulin monomer fold with application to structure-
activity relationships. Biochemistry 32: 10773–10778.
40. Schwartz GP, Burke GT, Katsoyannis PG (1987) A superactive insulin: [B10-
aspartic acid]insulin(human). Proc Natl Acad Sci USA 84: 6408–6411.
41. Scha ¨ffer L (1994) A model for insulin binding to the insulin receptor.
Eur J Biochem 221: 1127–1132.
42. Gauguin L, Delaine C, Alvino CL, McNeil KA, Wallace JC, et al. (2008)
Alanine scanning of a putative receptor binding surface of insulin-like growth
factor-I. J Biol Chem 283: 20821–20829.
43. Eckardt K, May C, Koenen M, Eckel J (2007) IGF-1 receptor signalling
determines the mitogenic potency of insulin analogues in human smooth muscle
cells and fibroblasts. Diabetologia 50: 2534–2543.
44. De Meyts P, Roth J, Neville DM, Gavin JR, Lesniak MA (1973) Insulin
interactions with its receptors: Experimental evidence for negative cooperativity.
Biochem Bioph Res Co 55: 154–161.
45. Moxham CP, Duronio V, Jacobs S (1989) Insulin-like growth factor-I receptor
beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-
like growth factor-I and insulin receptor heterodimers. J Biol Chem 264:
13238–13244.
46. Soos MA, Siddle K (1989) Immunological relationships between receptors for
insulin and insulin-like growth factor-I. Evidence for structural heterogeneity of
insulin-like growth factor-I receptors involving hybrids with insulin receptors.
Biochem J 263: 553–563.
47. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor
isoforms and insulin receptor/insulin-like growth factor receptor hybrids in
physiology and disease. Endocr Rev 30: 586–623.
48. Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and
lipid metabolism. Nature 414: 799–806.
49. Hamel FG, Siford GL, Fawcett J, Chance RE, Frank BH, et al. (1999)
Differences in the cellular processing of AspB10 human insulin compared with
human insulin LysB28ProB29 human insulin. Metabolism 48: 611–617.
50. Bennet RG, Fawcett J, Kruer MC, Duckworth WC, Hamel FG (2003) Insulin
inhibition of the proteasome is dependent on degradation of insulin by insulin-
degrading enzyme. J Endocrinol 177: 399–405.
51. Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, et al. (2010) Insulin
analogues differently activate insulin receptor isoforms and post-receptor
signalling. Diabetologia 53: 1743–1753.
52. Jensen M, Palsgaard J, Borup R, De Meyts P, Scha ¨ffer L (2008) Activation of the
insulin receptor (IR) by insulin and a synthetic peptide has different effects on
gene expression in IR-transfected L6 myoblasts. Biochem J 412: 435–445.
53. Rakatzi I, Ramrath S, Ledwig D, Dransfeld O, Bartels T, et al. (2003) A novel
insulin analog with unique properties: Lys(B3),Glu(B29) insulin induces
prominent activation of insulin receptor substrate 2, but marginal phosphory-
lation of insulin receptor substrate 1. Diabetes 52: 2227–2238.
54. Uhles S, Moede T, Leibiger B, Berggren PO, Leibiger IB (2007) Selective gene
activation by spatial segregation of insulin receptor B signaling. FASEB J 21:
1609–1621.
B10-Substituted Insulin Analogues
PLoS ONE | www.plosone.org 8 February 2012 | Volume 7 | Issue 2 | e29198